Human microbiomes, which have broad distribution throughout the body, can generate critical metabolic compounds. Through interactions between the host and microbiomes, potential biological processes could be regulated.
Microbiome diversity and specific metabolites could influence immune responses within the tumor microenvironment. It is well known that obesity is associated with several chronic diseases, such as diabetes, heart diseases, and cancers. Due to sustained weight loss and long-lasting metabolic benefits, bariatric surgery has become more prevalent in recent years. However, much work remains in related areas regarding the molecular basis for metabolic improvement after bariatric surgery.
A growing body of evidence indicates that these improvements are the result of metabolites like short-chain fatty acids (SCFAs) or bile acids (BAs) produced by microbiomes. According to recent research on metabolic and epigenetic reprogramming, SCFAs including pentanoate and butyrate could enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells. Besides, the antitumor immune responses could also be triggered and enhanced based on BAs by stimulating tumoricidal immune cells, such as natural killer T cells.
In this Research Topic, we aim to generate a collection of articles that discuss the impact of microbially modified metabolites induced by bariatric surgery upon obesity on anti-tumor immunity. We further focus on the changes in the proportion and type of microbially modified metabolites after surgery, as well as their roles in tumor metabolism. Of particular interest, these articles could shed light on the association of metabolites produced through the gut or extra-intestinal depots with tumor microenvironment and treatment efficiency.
We welcome the submission of Reviews, Original Research, Perspectives, Clinical Trials, and Systematic Review articles. Areas to be covered in this research topic may include, but are not limited to:
1) Epidemiologic or clinical research on the influence of microbially modified metabolites associated with obesity and bariatric surgery on the characteristics and prognosis of certain tumor types (e.g. breast cancer).
2) Applications of 16S rRNA phylogenetic marker and shotgun metagenomic or metatranscriptomic sequencing of the microbiome in obese patients with malignant tumors.
3) Analysis of mass spectrometry-based metabolomics, metaproteomics (e.g. BAs, SCFAs, and TMAO) before and after weight loss, and potential association with immune cell content and activation.
4) Mechanistic studies exploring the effects of microbially modified metabolites followed by bariatric surgery on the treatment efficiency of certain tumor types (e.g. Relationship between the postbariatric hormonal environment with tumor microenvironment).
5) New strategy and methodology to bridge bacteriomics, metabolomics, or genomics to investigate the connections between microbiota, bariatric surgery, and cancer prognosis.
6) Mechanisms of interactions between microbially modified metabolites, obesity, bariatric surgery, and anti-tumor immunity.
Human microbiomes, which have broad distribution throughout the body, can generate critical metabolic compounds. Through interactions between the host and microbiomes, potential biological processes could be regulated.
Microbiome diversity and specific metabolites could influence immune responses within the tumor microenvironment. It is well known that obesity is associated with several chronic diseases, such as diabetes, heart diseases, and cancers. Due to sustained weight loss and long-lasting metabolic benefits, bariatric surgery has become more prevalent in recent years. However, much work remains in related areas regarding the molecular basis for metabolic improvement after bariatric surgery.
A growing body of evidence indicates that these improvements are the result of metabolites like short-chain fatty acids (SCFAs) or bile acids (BAs) produced by microbiomes. According to recent research on metabolic and epigenetic reprogramming, SCFAs including pentanoate and butyrate could enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells. Besides, the antitumor immune responses could also be triggered and enhanced based on BAs by stimulating tumoricidal immune cells, such as natural killer T cells.
In this Research Topic, we aim to generate a collection of articles that discuss the impact of microbially modified metabolites induced by bariatric surgery upon obesity on anti-tumor immunity. We further focus on the changes in the proportion and type of microbially modified metabolites after surgery, as well as their roles in tumor metabolism. Of particular interest, these articles could shed light on the association of metabolites produced through the gut or extra-intestinal depots with tumor microenvironment and treatment efficiency.
We welcome the submission of Reviews, Original Research, Perspectives, Clinical Trials, and Systematic Review articles. Areas to be covered in this research topic may include, but are not limited to:
1) Epidemiologic or clinical research on the influence of microbially modified metabolites associated with obesity and bariatric surgery on the characteristics and prognosis of certain tumor types (e.g. breast cancer).
2) Applications of 16S rRNA phylogenetic marker and shotgun metagenomic or metatranscriptomic sequencing of the microbiome in obese patients with malignant tumors.
3) Analysis of mass spectrometry-based metabolomics, metaproteomics (e.g. BAs, SCFAs, and TMAO) before and after weight loss, and potential association with immune cell content and activation.
4) Mechanistic studies exploring the effects of microbially modified metabolites followed by bariatric surgery on the treatment efficiency of certain tumor types (e.g. Relationship between the postbariatric hormonal environment with tumor microenvironment).
5) New strategy and methodology to bridge bacteriomics, metabolomics, or genomics to investigate the connections between microbiota, bariatric surgery, and cancer prognosis.
6) Mechanisms of interactions between microbially modified metabolites, obesity, bariatric surgery, and anti-tumor immunity.
